<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083199</url>
  </required_header>
  <id_info>
    <org_study_id>PE0702</org_study_id>
    <nct_id>NCT01083199</nct_id>
  </id_info>
  <brief_title>Global Performance Evaluation of the AMS CONTINUUM™ Device</brief_title>
  <official_title>Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate
           sustainable vesico-urethral anastomosis during a radical prostatectomy procedure.

        2. To assess clinical outcomes of the Device in facilitating the vesico-urethral
           anastomosis following a radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical prostatectomy (RP) is the most utilized surgical treatment option for localized
      prostate cancer due to the multi-focal nature of the disease. RP is most suitable for
      otherwise healthy men whose cancer is limited to a small area. The RP procedure involves
      removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most
      technically challenging and critical aspects in all of these surgical approaches is
      reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral
      anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has
      been removed.

      CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the
      approximation of the bladder neck and urethral stump. The Device brings together and holds
      the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs
      thereby minimizing extravasation. The Device also provides a conduit for drainage of urine
      from the bladder out the urethra during tissue healing.

      The concept of the CONTINUUM™ device and the feasibility of its operation have been
      successfully tested in animal and human studies. Pilot clinical studies in the United States
      (G060095) found that the majority of subjects who received and were discharged with the
      Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal
      visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus
      of the proposed study is to further verify the performance of the Device in global research
      centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Device Placement</measure>
    <time_frame>During Radical Prostatectomy</time_frame>
    <description>Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement</measure>
    <time_frame>7-21 days post-Device placement</time_frame>
    <description>Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.
The following defines the timeframe of each removal attempt:
7-day window (7-10 days post-implant)
14-day window (13-15 days post-implant)
21-day window (19-21 days post-implant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative/Postoperative Parameters</measure>
    <time_frame>At Device placement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits</measure>
    <time_frame>7 and 14 days post-Device placement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Rate and I-QOL Score</measure>
    <time_frame>Baseline, 6-week, 6 and 12-month evaluations</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder Neck Contracture (BNC) Rate</measure>
    <time_frame>Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CONTINUUMTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONTINUUM™</intervention_name>
    <description>Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.</description>
    <arm_group_label>CONTINUUMTM</arm_group_label>
    <other_name>Anastomosis Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All males ≥ 40 years old who are indicated for a radical prostatectomy will be
             eligible to participate in the study

        Exclusion Criteria:

          -  If contraindicated for surgery

          -  Inability to understand the study or a history of non-compliance with medical advice

          -  Unwilling or unable to sign an Informed Consent Form (ICF)

          -  A history of:

               1. Recurrent urinary tract infections (UTI)

               2. Recurrent stricture disease

          -  Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease)

          -  Uncontrolled insulin-dependent diabetes

          -  Chemotherapy within the past 6 months

          -  Non-topical steroid use within the past 6 months

          -  Allergy to nitinol, nickel, titanium or silicone
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelos Liatsikos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital University Gregorio Maranon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Patras</name>
      <address>
        <city>Rio-Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2016</results_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Vesico-Urethral Anastomosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AMS CONTINUUM™ Device</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AMS CONTINUUM™ Device</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Device Placement</title>
        <description>Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.</description>
        <time_frame>During Radical Prostatectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuum Device</title>
          </group>
        </group_list>
        <measure>
          <title>Successful Device Placement</title>
          <description>Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement</title>
        <description>Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.
The following defines the timeframe of each removal attempt:
7-day window (7-10 days post-implant)
14-day window (13-15 days post-implant)
21-day window (19-21 days post-implant)</description>
        <time_frame>7-21 days post-Device placement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMS CONTINUUM™ Device</title>
          </group>
        </group_list>
        <measure>
          <title>Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement</title>
          <description>Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.
The following defines the timeframe of each removal attempt:
7-day window (7-10 days post-implant)
14-day window (13-15 days post-implant)
21-day window (19-21 days post-implant)</description>
          <units>participants with device removal by 21d</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative/Postoperative Parameters</title>
        <time_frame>At Device placement</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits</title>
        <time_frame>7 and 14 days post-Device placement</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incontinence Rate and I-QOL Score</title>
        <time_frame>Baseline, 6-week, 6 and 12-month evaluations</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bladder Neck Contracture (BNC) Rate</title>
        <time_frame>Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AMS CONTINUUM™ Device</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Separation/Distruption of Anastomosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>False Passage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rectal Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Separation/Disruption of Anastomosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Olson, Clinical Project Manager</name_or_title>
      <organization>American Medical Systems</organization>
      <phone>952-930-6428</phone>
      <email>laura.olson2@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

